$ News

Viracta Therapeutics Announces Wind Down of Operations

Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Viracta Therapeutics price target lowered by $2 at RBC Capital, here's why

Viracta Therapeutics just downgraded at Leerink, here's why

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Sunesis: Q2 Earnings Snapshot

Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?

Viracta jumps after corporate update

Viracta Therapeutics GAAP EPS of -$0.25 beats by $0.11

Viracta Therapeutics announces data from Phase 2 NAVAL-1 trial

Viracta Therapeutics reports Q2 EPS (25c) vs (32c) lastyear

Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M

Viracta Therapeutics price target lowered by $2 at Oppenheimer, here's why